05:23 PM EST, 01/09/2025 (MT Newswires) -- Repare Therapeutics ( RPTX ) said late Thursday it is refocusing its resources on advancing phase 1 clinical programs for RP-1664 in solid tumors and RP-3467 in certain types of cancer.

The company also intends to seek partnerships for lunresertib and camonsertib before starting the next trials.

The strategic realignment, combined with cost and headcount reductions, is expected to extend the company's funds of $153 million until mid-2027, it added.

Repare said it will discontinue other lunresertib and camonsertib studies unless a suitable development partner is found.